Neutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough

Yichuan Yao, Yunru Yang, Qiqin Wu, Mengyao Liu, Wei Bao, Qiutong Wang, Meijun Cheng, Yunuo Chen, Yiting Yu, Yuan Cai, Mei Zhang, Jingxue Yao, Hongliang He, Changjiang Jin, Changcheng Zheng, Tengchuan Jin, Dali TongEuropean 2025 · DOI

Abstract

This observational study investigates the immune response of individuals in Hefei, China, following a major SARS-CoV-2 Omicron BA.5/BF.7 breakthrough infection wave in late 2022. The research specifically examines how age and vaccination history influence the production of neutralizing antibodies against emerging variants, providing critical data on the phenomenon of "immune imprinting" in younger populations.

Introduction

The rapid evolution of SARS-CoV-2 into the Omicron lineage has challenged the efficacy of original (prototype) vaccines. A significant concern in immunology is "immune imprinting," where repeated exposure to an original antigen prevents the immune system from effectively responding to new variants. While this has been documented in older populations, its impact on younger individuals remains less clear. This study evaluates whether prototype vaccine boosters still offer functional benefits to young people facing highly mutated strains like BA.5, BF.7, and XBB.1.5.

Methods

The researchers analyzed blood samples from a cohort of 636 volunteers at the USTC Hospital in Anhui Province, China. The immune response was quantified using three primary methods:

  • Chemical Luminescence Assay: To measure overall IgG, IgA, and IgM levels against the prototype receptor-binding domain (RBD).
  • ELISA: To determine specific IgG titers for prototype, BA.5, BF.7, and XBB.1.5 RBDs.
  • Pseudovirus-Based Neutralization Assay: To measure the 50% pseudovirus neutralizing titer ($pVNT_{50}$), which indicates the functional ability of antibodies to block viral entry into cells.

Results and Discussion

The study found that age is a primary determinant of the robust antibody response following a breakthrough infection. Younger individuals (<60 years) demonstrated significantly higher levels of SARS-CoV-2 specific IgG compared to older individuals (>60 years).

Comparison of SARS-CoV-2 IgG levels (COI) between uninfected/infected individuals (A) and across age groups (B).

As shown in the figure above, while infection naturally leads to a surge in IgG levels (Panel A), the magnitude of this response is attenuated in the elderly (Panel B). This suggests that the dampening effects of immune imprinting or immunosenescence are more pronounced in older cohorts.

The Synergistic Effect of Boosters

A key finding was the necessity of booster doses (3rd or 4th dose) to prime the immune system for a cross-reactive defense. Individuals who received only a 2-dose primary series before infection did not show significantly higher neutralizing titers than unvaccinated individuals. However, those with 3 or 4 doses exhibited a massive increase in $pVNT_{50}$ against the prototype, BA.5, and BF.7 variants following breakthrough infection. This indicates that in younger populations, prototype boosters successfully "prime" the immune system to update its repertoire when encountering a live variant.

Limits of Cross-Immunity: The XBB.1.5 Variant

Despite the success against BA.5 and BF.7, the study highlighted a critical threshold for viral escape. The XBB.1.5 variant, characterized by extensive mutations, almost entirely evaded the neutralizing antibodies generated by both prototype vaccination and BA.5/BF.7 infection. Neutralizing titers against XBB.1.5 remained uniformly low across all study groups, regardless of booster status.

Conclusion

While prototype vaccine boosters remain highly effective at enhancing the immune response to closely related Omicron sub-lineages in younger individuals, they offer limited protection against more distant variants like XBB.1.5. These results support the continued use of booster strategies for young populations but emphasize the urgent need for updated, broad-spectrum vaccines to address the ongoing evolution of the virus.

Summary updated

Abstract

This study is a purely observational study.
BibTeX
@inproceedings{yao2025neutralizing,
  author = {Yichuan Yao and Yunru Yang and Qiqin Wu and Mengyao Liu and Wei Bao and Qiutong Wang and Meijun Cheng and Yunuo Chen and Yiting Yu and Yuan Cai and Mei Zhang and Jingxue Yao and Hongliang He and Changjiang Jin and Changcheng Zheng and Tengchuan Jin and Dali Tong},
  title = {{Neutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough}},
  booktitle = {European},
  year = {2025},
  doi = {10.1186/s40001-024-02240-5},
}
Figure